New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
08:57 EDTARQL, TRGTTargacept names Stephen A. Hill, M.D., president and CEO
Dr. Hill is expected to start with Targacept (TRGT) on December 1 and will also join Targaceptís Board of Directors. Dr. Hill brings over 20 years of industry experience to the role, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and ArQule (ARQL). Upon Dr. Hill joining Targacept, the previously formed Office of the Chairman will be dissolved.
News For TRGT;ARQL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
08:31 EDTTRGTTargacept says TC-6499 did not meet primary endpoint in Phase 1/2 study
Subscribe for More Information
April 6, 2015
10:37 EDTTRGTTargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalystís leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use